Peptide leukotriene receptor antagonism in myocardial ischaemia and reperfusion

C E Hock1, L D Beck, L A Papa

  • 1Department of Medicine, University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Stratford 08084.

Cardiovascular Research
|December 1, 1992
PubMed

Insights

The peptide leukotriene receptor antagonist LY-171883 significantly reduced myocardial injury during reperfusion in cats. This indicates peptide leukotrienes play a role in extending ischaemic damage and post-ischaemic dysfunction.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Pathophysiology

Background:

  • Myocardial ischaemia-reperfusion injury is a significant clinical problem.
  • Peptide leukotrienes (PLTs) are implicated in inflammatory processes and tissue damage.

Purpose of the Study:

  • To investigate the role of PLTs in myocardial injury during reperfusion.
  • To evaluate the efficacy of the PLT receptor antagonist LY-171883 in reducing ischaemia-reperfusion injury.

Main Methods:

  • Adult male cats underwent coronary artery occlusion followed by reperfusion.
  • The PLT receptor antagonist LY-171883 was administered during reperfusion.
  • Myocardial injury was assessed by infarct size, creatine kinase, and neutrophil infiltration (myeloperoxidase activity).

Main Results:

  • LY-171883 treatment significantly reduced the necrotic area of the myocardium (48% vs 29% of area at risk).
  • Creatine kinase activity was higher in the area at risk in the drug-treated group, indicating less damage.
  • Neutrophil infiltration, measured by myeloperoxidase activity, was not significantly reduced by LY-171883.

Conclusions:

  • LY-171883 demonstrated a protective effect against myocardial ischaemia-reperfusion injury.
  • These findings support a role for PLTs in the extension of ischaemic damage and post-ischaemic ventricular dysfunction.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...